An Ascending Multiple-Dose Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NSA-789 Administered Orally to Subjects With Schizophrenia or Schizoaffective Disorder.
Phase of Trial: Phase I
Latest Information Update: 09 Dec 2009
At a glance
- Drugs NSA 789 (Primary)
- Indications Schizoaffective disorder; Schizophrenia
- Focus Adverse reactions
- 21 Jul 2009 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 12 May 2009 New trial record